
On Friday, January 17, the Biden Administration released its list of 15 drugs which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the second round of drug price negotiations for 2027 as part of the Inflation Reduction Act (IRA).
Highlights include:
- Drug manufacturers will have until February 28, 2025, to opt in to, or out of, negotiations with the federal government.
- The new 15 drugs, plus the existing agreed-upon 10 drugs (effective January 1, 2026), account for more than a third of seniors’ drug spending.
- The first 10 drugs focus on diabetes, heart disease, rheumatoid arthritis, and cancer.
- The new list prices for the 10 drugs reflect 39%–79% discounts compared to their former prices.
- Program deadlines are typically statutory in nature, however, any possible future impact of the new administration is unknown at this time.
- Most Group members have fixed copays, so they may not see a reduction in copay unless they have a percentage copay. However, lowering drug costs overall would help contribute positively to actuarial pricing models.

For further details, you can explore these resources: